Chronic kidney disease (CKD) is driven by persistent inflammation that also increases cardiovascular disease risk. Researchers are investigating novel anti-inflammatory therapies that directly target specific immune pathways rather than treating symptoms. Current clinical trials are testing drugs that block inflammatory molecules like interleukin-1, interleukin-6, and the NLRP3 inflammasome. Other approaches include activating protective cellular pathways and using senolytic drugs that eliminate aging cells. These targeted treatments represent a promising shift from traditional CKD management toward addressing root inflammatory causes. Phase 3 trials are ongoing to determine effectiveness and safety.
